Chimerix, a Durham biopharmaceutical company, said Tuesday it raised $16.1 million to continue testing antiviral drugs for treating smallpox.
The latest round of financing brings the seven-year-old company’s total haul to $56 million, but Chimerix is still at least several years away from having a commercial product, said chief operating officer Kenneth Moch.
